



THE CANADIAN CANCER RESEARCH CONFERENCE | LA CONFÉRENCE CANADIENNE SUR LA RECHERCHE SUR LE CANCER



# VIRTUAL PROGRAM PROGRAMME DE LA CONFÉRENCE VIRTUELLE

---

November 12 - 14, 2023

Halifax, NS

12 au 14 novembre 2023

Halifax, NS

[ccra-acrc.ca/conference](https://ccra-acrc.ca/conference)

# CONFERENCE OVERVIEW – Virtual

## Sunday, November 12, 2023

12:40 pm Welcome Remarks

2:10 pm Plenary Session – Liquid Biopsies

3:50 pm Break

4:10 pm Plenary Session – AI Across the Research Spectrum

5:40 pm Break

6:10 pm Lightning Sessions

Bioinformatics, Big Data, AI and Technology

Survivorship

## Monday, November 13, 2023

### Concurrent Sessions

12:40 pm Health Equity Innovations in Clinical Trials Improving the Cancer Journey of First Nations, Inuit and Métis

2:10 pm Break

2:40 pm Plenary Session – Clinical Innovations in the Real World

4:10 pm Break

### Concurrent Sessions

4:40 pm Enhancing Palliative, End-of-Life, and Survivorship Experiences Adolescent and Young Adult Cancer Tumour Microenvironment

6:10 pm Break

### Lightning Sessions

6:50 pm Metastasis Screening, Early Detection, Diagnosis and Prognosis

## Tuesday, November 14, 2023

11:40 am Plenary Session – Environment and Cancer

### Lightning Sessions

1:10 pm Metabolism Patient Experience and Advocacy

1:40 pm Break

### Concurrent Sessions

2:10 pm The Gut Microbiome for Precision Oncology Advances in Cancer Biology Reducing Your Risk of Cancer Recent Advances in Cancer Treatment

3:40 pm Closing Remarks

**\*Scientific Program subject to change**

The following plenary sessions will be available online via live stream: AI Across the Research Spectrum, Clinical Innovations in the Real World, and Environment and Cancer

All other sessions listed will be recorded and made available at the times listed above.

# APERÇU DU PROGRAMME – Virtuel

## Dimanche 12 novembre 2023

12 h 40 Mot de bienvenue

14 h 10 Séance plénière – Les biopsies liquides

15 h 50 Pause

16 h 10 Séance plénière – L'IA dans tous les domaines de la recherche

17 h 40 Pause

18 h 10 Séances éclair

La bio-informatique, les mégadonnées, l'IA et la technologie

La survie

## Lundi 13 novembre 2023

### Séances simultanées

12 h 40 L'équité en santé Les innovations dans les essais cliniques Améliorer le parcours face au cancer des Premières Nations, des Inuits et des Métis

14 h 10 Pause

14 h 40 Séance plénière – Les innovations cliniques dans le monde réel

16 h 10 Pause

### Séances simultanées

16 h 40 Améliorer les expériences des soins palliatifs, des soins de fin de vie et de la survie Le cancer chez les adolescents et les jeunes adultes Le micro-environnement tumoral

18 h 10 Pause

### Séances éclair

18 h 50 Les métastases Le dépistage, la détection précoce, le diagnostic et le pronostic

## Mardi 14 novembre 2023

11 h 40 Séance plénière – L'environnement et le cancer

### Séances éclair

13 h 10 Le métabolisme L'expérience des patients et la défense de leurs intérêts

13 h 40 Pause

### Séances simultanées

14 h 10 Le microbiome intestinal pour l'oncologie de précision Progrès accomplis dans la biologie du cancer Réduire votre risque de cancer Progrès accomplis dans les traitements contre le cancer

15 h 40 Mot de la fin

\* Programme sujet à changement

Les séances plénières seront accessibles en ligne par le biais d'une diffusion en continu en direct : L'IA dans tous les domaines de la recherche, Les innovations cliniques dans le monde réel, et L'environnement et le cancer.

Toutes les autres séances seront enregistrées et accessibles aux heures indiquées ci-dessus.

# SUNDAY, NOVEMBER 12, 2023

12:40 pm

## Welcome Remarks

**Catherine Martin**

*Director Indigenous Engagement, Member of Millbrook Mi'kmaw community*

**Dr. Sara Urowitz**

*Canadian Cancer Research Alliance, Canadian Partnership Against Cancer*

**Dr. Paula Robson**

*Alberta Health Services, Canadian Cancer Research Alliance*

**Dr. Helmut Hollenhorst**

*Nova Scotia Health Cancer Care Program, Dalhousie University*

**Dr. Jim Woodgett**

*Terry Fox Research Institute, Lunenfeld-Tanenbaum Research Institute*

**Dr. Sherri Christian**

*Memorial University of Newfoundland, Beatrice Hunter Cancer Research Institute, Marathon of Hope Cancer Centres, Terry Fox Research Institute*

**Dr. Robin Urquhart**

*Dalhousie University, Atlantic Partnership for Tomorrow's Health, Beatrice Hunter Cancer Research Institute, Nova Scotia Health Authority*

2:10 pm

## Plenary Session – Liquid Biopsies

Chairs:

**Dr. Sherri Christian**

*Memorial University of Newfoundland, Beatrice Hunter Cancer Research Institute, Marathon of Hope Cancer Centres, Terry Fox Research Institute*

**Ms. Melissa Coombs**

*Patient Partner*

Predicting Response to Immune Checkpoint Therapy with Extracellular Vesicle Liquid Biopsy

The Clinical Utility of Liquid Biopsies in Lung Cancer

CHARMing Hereditary Cancer: Surveillance for Early Cancer using Cell-Free DNA Sequencing

**Dr. Rodney Ouellette**

*Atlantic Cancer Research Institute*

**Sameena Khan**

*Princess Margaret Cancer Centre, University of Toronto*

**Dr. Trevor Pugh**

*Princess Margaret Cancer Centre, University of Toronto*

3:50 pm

Break

4:10 pm

## Plenary Session – AI Across the Research Spectrum

Chairs:

**Dr. Ali Bashashati**

*University of British Columbia, Vancouver Coastal Health Research Institute*

**Dr. Rosilene Kraft**

*Patient Partner*

Ethics of AI in Radiology

Development and commercialization of machine learning models to predict disease

**Dr. Manisha Bahl**

*Mass General Research Institute, Harvard University*

**Dr. Muhammad Mamdani**

*Unity Health, St. Michael's Hospital, University of Toronto*

**Dr. John Lewis**

*Faculty of Medicine & Dentistry, University of Alberta*

5:40 pm

Break

**Bioinformatics, Big Data, AI and Technology**

Single-cell RNAseq identifies tumour stem-cell fate driven by lipid metabolism in liver cancer

**Dr. Tallulah Andrews**  
University of Western Ontario

Exploring Cell Composition and Molecular Markers in Wilms Tumor for Improved Risk Stratification and Treatment

**Mr. Fabian Bong**  
Dalhousie University

Developing the pan-Canadian Cancer Data Strategy (cancer data strategy) to guide cancer data improvements and implementation efforts

**Ms. Natalie Fitzgerald**  
Canadian Partnership Against Cancer

Gaining insights into high risk AML through the integration of drug screening, RNA-seq, and Epigenetic Profiling

**Miss Safia Safa-tahar-henni**  
IRIC/Université de Montréal

Automated tumour group classification from cancer electronic pathology reports using pre-trained language models

**Dr. Jonathan Simkin**  
BC Cancer, Provincial Health Services Authority

ARS2 Association with subnuclear Paraspeckles: Implications for Hepatocellular Carcinoma Progression and Drug Resistance

**Dr. Gobi Thillainadesan**  
Sunnybrook Research Institute

Privacy Risks of Machine Learning Models: Systematic Review and Meta-Analysis of Membership Inference Attacks and Implications for Data Security

**Dr. Emily Walker**  
Cancer Care Alberta, Alberta Health Services

LncRNAs exhibit subtype-specific expression, survival associations, and cancer-promoting effects in breast cancer

**Miss Marie-Claire Wasson**  
Dalhousie University

**Survivorship**

Virtually Supervised Exercise for People with Advanced Lung Cancer: Feasibility and Physical Function Results

**Dr. Kristin Campbell**  
University of British Columbia

Missed Opportunities in Supporting Informal Cancer Caregiver (and Patient) Health

**Mr. Thomas Christensen**  
Dalhousie University

Adherence to Breast Cancer Screening Guidelines and Risk of Breast Cancer-Specific Death

**Dr. Rebecca Christensen**  
Dalla Lana School of Public Health

Development of a polygenic score to predict cisplatin-induced ototoxicity

**Dr. Britt Drogemoller**  
University of Manitoba

Adjuvant Treatment in High-Grade Serous Endometrial Carcinoma: A Comprehensive Institutional Review

**Dr. Sedighe Esmailzade**  
McGill University Health Center

Evaluating the association between pre-diagnostic routine lipid measurements and mortality among breast cancer survivors: A population-based retrospective cohort study

**Miss Shana Kim**  
University of Toronto

Finding Intimacy Without Sex: Exploring the impact of lost intimacy and sexual function after cancer

**Ms. Cecile Proctor**  
University of New Brunswick

Strategies to increase acceptance of referral to smoking cessation at an Ontario regional cancer centre

**Dr. Deborah Saunders**  
Northeast Cancer Centre, Health Sciences North

Mental Health Status of Prostate Cancer Survivors in the Atlantic PATH Cohort

**Dr. Ellen Sweeney**  
Dalhousie University

# MONDAY, NOVEMBER 13, 2023

12:40 am

## CONCURRENT SESSIONS

### Health Equity

Chair:

**Dr. David Busolo**

*University of New Brunswick, Faculty of Nursing, Moncton Campus, Beatrice Hunter Cancer Research Institute*

**Sundas Shamshad**

*Patient Partner*

Prevention of Cervical Cancer in India through Self-Sampling (PCCIS)

**Dr. Mandana Vahabi**

*Toronto Metropolitan University*

Exploring primary care provider barriers and enablers to implementation of cancer screening with patients experiencing marginalization

**Dr. Arlinda Ruco**

*St. Francis Xavier University*

Disparities In Clinical Trial Enrolment At A Canadian Comprehensive Cancer Centre: A Fifteen-Year Retrospective Study

**Dr. Gilla Shapiro**

*Princess Margaret Cancer Centre*

Cancer incidence in people with intellectual or developmental disabilities: Two population-based retrospective cohort studies in Manitoba and Ontario, Canada

**Dr. Alyson Mahar**

*Queen's University*

### Innovations in Clinical Trials

Chair:

**Dr. Wendy Parulekar**

*Canadian Cancer Trials Group, Queen's University*

**David McMullen**

*Patient Partner*

An Overview of Accelerated Clinical Trials (ACT) Canada

**Dr. PJ Devereaux**

*McMaster University*

Implementation of the Canadian Remote Access Framework for Clinical Trials (CRAFT), a model for decentralized clinical trials (DCT)

**Mr. Stephen Sundquist**

*3CTN - Canadian Cancer Clinical Trials Network*

Cost-Effectiveness Analysis of the Prostate Cancer Patient Empowerment Program (PC-PEP)

**Ms. Alexandra Nuyens**

*Dalhousie University*

A phase IIb randomized placebo-controlled trial testing a long-chain omega-3 fatty acid MAG-EPA dietary supplement on prostate cancer aggressiveness

**Dr. Farah Ben Souilah**

*CHU de Québec - Université Laval*

### Improving the Cancer Journey of First Nations, Inuit and Métis

Chair:

**Gail Turner**

*Canadian Partnership Against Cancer*

A Qualitative Exploratory Study to Support the Elimination of Cervical Cancer in Canada's Indigenous Communities: Alberta Métis Settlement Perspectives

**Dr. Angeline Letendre**

*Canadian Indigenous Nurses Association*

The Giant Colon - Increasing Colorectal Cancer Screening Rates through Community Engagement: Manitoba

**Mrs. Laryssa Sawchuck**

*CancerCare Manitoba*

**Tracy Abraham**

*Interlake-Eastern Regional Health Authority*

Courage, Compassion and Connection: exploring of the pre-diagnosis cancer journey for Labrador's Indigenous populations

**Dr. Jennifer Shea**

*Memorial University*

2:10 pm

Break

2:40 pm

**Plenary Session – Clinical Innovations in the Real World**

Chairs:

**Dr. Sachin Katyal**

*University of Manitoba, CancerCare Manitoba*

**Ms. Ruth Ackerman**

*Patient Partner*

Multiple myeloma: a bench-to bedside perspective with patients as partners

**Dr. Tony Reiman**

*Atlantic Cancer Research Institute, Beatrice Hunter Cancer Research Institute, Dalhousie University, University of New Brunswick*

Understanding clonal evolution in recurrent medulloblastoma: In vivo modeling and cancer-selective drug discovery and design

**Dr. Sheila Singh**

*Cancer Research Centre, McMaster University*

Family Ties to Cancer: Innovative primary care strategies for hereditary cancer risk

**Dr. June Carroll**

*Faculty of Medicine, University of Toronto, Granovsky Gluskin Family Medicine Centre, Sinai Health*

4:10 pm

Break

4:40 pm

**CONCURRENT SESSIONS**

**Enhancing Palliative, End-of-Life, and Survivorship Experiences**

Chair:

**Dr. Harvey Chochinov**

*University of Manitoba*

**Sandra Dudych**

*Patient Partner*

The impact of a cancer diagnosis on the short- and long-term income of cancer survivors in Canada

**Dr. Stuart Peacock**

*Canadian Centre for Applied Research in Cancer Control (ARCC)*

Knowledge products to support the knowledge translation of exercise recommendations for people with bone metastases: an experience-based co-design approach

**Dr. Kelcey Bland**

*University of British Columbia*

Edmonton Classification System for Cancer Pain: Comparison of Pain Classification Features and Pain Intensity across Diverse Palliative Care Settings in Canada

**Dr. Mathieos Beylانه**

*University of British Columbia*

The Patient Dignity Question: Eliciting Personhood in Clinical Care

**Dr. Harvey Chochinov**

*University of Manitoba*

**Adolescent and Young Adult Cancer**

Chair:

**Dr. Uri Tabori**

*The Hospital for Sick Children*

**Karen Haas**

*Patient Partner*

CANON – The Canadian Adolescents and young adults NeuroOncology Network: From discovery to patient care

**Dr. Uri Tabori**

*The Hospital for Sick Children*

Developing a machine learning classifier for the diagnosis of Li-Fraumeni Syndrome

**Ms. Brienne Laverty**

*The Hospital for Sick Children*

Investigation of RAS-dependent and -independent functions of NF1: implications for targeted and immune therapies in melanoma

**Dr. Ian Watson**

*McGill University*

Sponsored by:



**SickKids**

**Garron Family  
Cancer Centre**

---

## Tumour Microenvironment

Chair:

**Dr. J. Patrick Murphy**

*Department of Biology, University of Prince Edward Island, Department of Pathology, University of Prince Edward Island, Beatrice Hunter Cancer Research Institute*

**Megan Emily Quintal**

*Patient Partner*

Prognosis and chemoresistance in ovarian cancer: the role of immune marker expression

**Dr. Arvind Mer**

*University of Ottawa*

A new patient-derived organoid culture with adipocytes allows the identification of de novo resistant ER+ breast tumors to endocrine therapies

**Dr. Afshin Raouf**

*University of Manitoba*

Nuclear localization deficient IL-33 orchestrates a potent anti-tumorigenic microenvironment via the recruitment and programming of glioma inhibitory macrophage

**Mr. Shyam Menon**

*Lady Davis Institute, McGill University*

The role of ICAM1 in glioblastoma tumorigenesis under hypoxic conditions

**Ms. Kaviya Devaraja**

*University of Toronto*

---

**6:10 pm**

**Break**

---

**6:50 pm**

**LIGHTNING SESSIONS**

---

## Metastasis

Investigation of roles of DNA methylation inhibition and STING agonist in the treatment of metastatic triple-negative breast cancer

**Dr. Sofiane Berrazouane**

*Lady Davis Institute, McGill University*

Overcoming Therapeutic Resistance by Targeting Ferroptosis in Cancer Cells Undergoing Anastasis

**Miss Rachel Hausman**

*University of British Columbia, BC Cancer Research Centre*

The Benefits and Limitations of dPCR in Detection of Minimal Residual Disease in Stage IV Colorectal Cancer

**Dr. Lucyna Krzywon**

*McGill University Health Centre Research Institute*

Trastuzumab and denosumab in the treatment of metastatic HER2-positive breast cancer: a case series and potential synergistic effect to explain their unusually long survival times

**Mr. Rahman Ladak**

*Schulich School of Medicine and Dentistry, Western University*

High Intratumoral Levels of Coco Leads to Vascular Dysfunction and Increased Tumor Aggressiveness

**Mr. Kevin Lanthier**

*Maisonneuve-Rosemont Research Center*

Exploring a link among protein synthesis, mitochondrial dysfunction, and epithelial-to-mesenchymal transition

**Dr. Stephen Lewis**

*Atlantic Cancer Research Institute*

Promotion of thrombin activatable fibrinolysis inhibitor (TAFI) activation in tumour microenvironment attenuates breast cancer metastasis in vivo

**Ms. Tasnim Reza**

*University of Western Ontario*

Counterbalance between Wnt/ $\beta$ -catenin and ATF2-dependent signalling pathways drives cancer cell invasion and intravasation

**Dr. Konstantin Stoletov**

*University of Alberta*

The impact of verteporfin on lung metastasis in a mouse model of advanced osteosarcoma

**Dr. Alicia Vilorio-Petit**

*University of Guelph*

---

**Screening, Early Detection, Diagnosis and Prognosis**

Cancer Stem Cell Marker ALDH1A3 Mediates Invasion in Triple-Negative Breast Cancer by Inducing Plasminogen Activation

**Dr. Alamelu Bharadwaj**  
*Dalhousie University*

Hospital-based personalized circulating tumor DNA tests for the identification of extremely good prognosis patients with residual Triple Negative Breast Cancer

**Ms. Anna Klemantovich**  
*Segal Cancer Centre, Lady Davis Institute,  
Jewish General Hospital*

DNA Organization Measurements from All the Individual Cells Within Tissue can be Highly Predictive of Cancer Cell Aggressiveness

**Dr. Calum MacAulay**  
*BC Cancer*

Self-Collection for Cervix Screening in Never and Under-screened in the British Columbia, Organized Cervix Screening Population-Based Program: Preliminary Program Findings

**Dr. Gina Ogilvie**  
*UBC, Women's Health Research Institute*

Is Canada prepared for Primary HPV-testing in Cervical Cancer Screening? A national study of the Knowledge, Attitudes, and Beliefs of Under and Adequately Screened Canadians

**Dr. Samara Perez**  
*McGill University Health Center*

CervixCheck: Outcomes of a digital approach to self-collected cervical screening in a low-uptake region of British Columbia, Canada

**Ms. Laurie Smith**  
*BC Cancer and Women's Health Research  
Institute*

Characterizing liquid biopsy signature in a chemotherapy resistant model of esophageal adenocarcinoma

**Dr. Julia Burnier**  
*McGill University*

Making Progress in Cancer Control: The Number of Cancer Deaths Avoided in Canada

**Dr. Matt Warkentin**  
*University of Calgary*

---

11:40 am

## Plenary Session – Environment and Cancer

Chairs:

### Dr. Robin Urquhart

Dalhousie University, Atlantic Partnership for Tomorrow's Health, Beatrice Hunter Cancer Research Institute, Nova Scotia Health Authority

### Dr. Don Desserud

Patient Partner

Indigenous-led Conservation and Environmental Wellness

Lifetime radon exposure as a future lung cancer screening eligibility criterion in Canada: pilot study outcomes and upcoming clinical trial details

Climate, Health & Sustainable Care

### Ms. Carol Crowe

Indigenous Visions Inc.

### Dr. Aaron Goodarzi

Cumming School of Medicine, University of Calgary

### Dr. Fiona Miller

Centre for Sustainable Health Systems, Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto

1:10 pm

## LIGHTNING SESSIONS

### Metabolism

XP01/CRM1 inhibition modulates autophagy and protein metabolism in cancer cells

### Mrs. Sophie Landry

Université de Moncton

ALDH1A3 regulates key processes that required for breast cancer cell plasticity and progression

### Dr. Wasundara Fernando

Dalhousie University

Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations

### Ms. Helgi Kuzmychova

University of Manitoba

Fatty acid  $\beta$ -oxidation enzyme ECI1 drives aggressive prostate cancer phenotype and predicts poor clinical outcome

### Dr. Jacques Lapointe

McGill University

Delineating and targeting a novel metabolism-based post-translational mechanism regulating the abundance of the 'undruggable' oncoprotein c-MYC in medulloblastoma

### Emma Martell

University of Manitoba

The secret life of a Krebs Cycle enzyme in aggressive cancers and optic neuropathies

### Dr. Michael Moran

Hospital for Sick Children, University of Toronto

### Patient Experience and Advocacy

Co-creation of a patient engagement strategy in cancer research funding

### Ms. Suzanne Bays

Canadian Cancer Society

Prostatic Specific Antigen Screening and Prostate Biopsy Procedure Experiences for Men at Risk of Prostate Cancer: Preliminary Results of the Biomarkers and Prostate Cancer Prevention and Environment (BIOCaPPE) Study

### Mrs. Farah Ben Souilah

CHU de Québec, Université Laval

Mental Health Among People Living With and Beyond Colorectal Cancer: A Patient-Oriented Constructivist Grounded Theory

### Dr. Vicki Cheng

University of British Columbia

The Rethinking Clinical Trials (REaCT) program: transforming pragmatic, practice-changing, patient-centred research across Canada

### Dr. Marie-France Savard

The Ottawa Hospital Research Institute

Ethical issues experienced in relationships between patients and other team members developing a strategy for meaningful patient engagement in cancer research funding

### Dr. Jenny Leese

University of Ottawa

How do patients with hereditary cancer syndromes navigate the healthcare system? A qualitative comparative study across Canada

### Ms. Brooklyn Sparkes

Memorial University of Newfoundland

Ethics as an enabler in co-design: Example of the Alberta Cancer Diagnosis Initiative

### Dr. Fay Strohschein

University of Calgary, Alberta Health Services

Mise à l'échelle du programme PAROLE-Onco: Le partenariat de soins et de services au bénéfice des patients et de leurs proches touchés par le cancer pour améliorer leur expérience tout au long de la trajectoire de soins

### Mrs. Cécile Vialaron

Centre de recherche du CHUM

## CONCURRENT SESSIONS

**The Gut Microbiome for Precision Oncology**

Chair:

**Dr. Bertrand Routy**  
*CHUM / CRCHUM***Darren Frew**  
*Patient Partner*

The rapid development of the gut microbiome as one of the hallmarks of cancer

**Dr. Bertrand Routy**  
*CHUM / CRCHUM*

Distinct gut microbiome clusters in high-grade prostate cancer patients influence the antitumor efficacy of anti-PD-1 immunotherapy in mice

**Mr. Jalal Laaraj**  
*Centre de Recherche du CHU de Québec-  
Université Laval*

The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids

**Mr. Jalal Laaraj**  
*Centre de Recherche du CHU de Québec-  
Université Laval*

Linking tumour, blood and oral microbiomes with cancer outcomes

**Dr. Robyn Wright**  
*Dalhousie University***Advances in Cancer Biology**

Chair:

**Dr. Paola Marcato**  
*Department of Pathology, Dalhousie University***Dr. John K Mark**  
*Patient Partner*

Genome-Wide CRISPR Cas9 Screen Reveals a PARG - PTEN - Dependent Vulnerability in Melanoma

**Mr. Emmanuel Asante**  
*McGill University*

Cataloguing and characterizing the chromosomes affected by genomic cataclysms in mantle cell lymphoma

**Dr. Krysta Coyle**  
*Simon Fraser University*

Improving the cancer survivorship narrative by implanting artificial Intelligence along the health care continuum

**Dr. Paola Marignani**  
*Dalhousie University***Reducing Your Risk of Cancer**

Chair:

**Shantelle Gould**  
*Partner***Dr. Rachel Murphy**  
*BC Cancer Research Centre, University of British Columbia*

You are what you eat but what if you are where you live?

**Dr. Rachel Murphy**  
*BC Cancer Research Centre, University of British  
Columbia*

There is kind of this awkward pressure that I should be doing it: Factors influencing youth vaping uptake

**Dr. Laura Struik**  
*University of British Columbia*

Exploring the Etiology of Rare Cancers Using a Large Occupational Cohort

**Dr. Paul Demers**  
*Occupational Cancer Research Centre, Ontario  
Health*

The effectiveness and cost-effectiveness of population-level policies to reduce alcohol use: a systematic umbrella review

**Ms. Umaima Abbas**  
*University of Western Ontario*

---

## Recent Advances in Cancer Treatments

Chair:

**Dr. Franco Vizeacoumar**

*Saskatchewan Cancer Agency, University of Saskatchewan*

**John Corriveau**

*Patient Partner*

Unique transcriptome profile at the leading edge of tumours point to the therapeutic vulnerabilities

Investigation of novel anti-leukemic compounds uncovered through high-throughput screening of human model leukemias

EZH2 inhibition circumvents PRAME-mediated retinoid resistance in keratinocyte carcinomas

Targeting colorectal liver metastases with Alpha radiation emitting device - A pre-clinical study

**Dr. Pinaki Bose**

*University of Calgary*

**Mrs. Karla Lucia Paez Martinez**

*Université de Montréal*

**Mr. Brandon Ramchatesingh**

*McGill University*

**Dr. Oran Zlotnik**

*McGill University Health Center Research Institute*

---

**3:40 pm**

**Closing Remarks**

**Dr. Sara Urowitz**

*Canadian Cancer Research Alliance, Canadian Partnership Against Cancer*

**Dr. Louisa Salemi**

*Canadian Cancer Research Alliance, Canadian Partnership Against Cancer*

**Catherine Martin**

*Director Indigenous Engagement, Member of Millbrook Mi'kmaw community*

---

**\*Scientific Program subject to change**

November 2023